PegBio Co., Ltd. (HKG:2565)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
64.60
+0.40 (0.62%)
At close: Feb 27, 2026
Market Cap 25.26B
Revenue (ttm) n/a
Net Income (ttm) -242.62M
Shares Out 391.09M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 224,000
Average Volume 236,313
Open 64.20
Previous Close 64.20
Day's Range 63.80 - 65.75
52-Week Range 8.68 - 77.00
Beta n/a
RSI 49.32
Earnings Date May 18, 2026

About PegBio

PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. Its products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company’s PB-718 that is in b/IIa clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 that is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 58
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2565
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.